Company intelligence / Profile preview
Halia Therapeutics
Lehi/Salt Lake City*, Utah, USAhaliatx.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Halia’s lead candidate HT‑6184—a first-in-class NEK7/NLRP3 inhibitor—has completed a Phase I study demonstrating safety/tolerability in healthy volunteers. Two Phase II trials have been launched targeting chronic inflammation-driven conditions including obesity/metabolic dysfunction and LR-MDS. Preclinical data show broad anti-inflammatory effects across multiple organ systems.
- Therapeutic areas
- GastroenterologyMetabolic DisordersImmunologyDermatologyHematologyNeurology
- Modalities
- Small molecules (allosteric modulators)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Novo Nordisk Golden Ticket/BioLabs European Award recipient for obesity/inflammation research support and mentorship from Novo Nordisk advisors.
Beyond the preview
Go deeper on Halia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halia Therapeutics.